We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+24.75%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$562M
AUM Growth
-$50.5M
Cap. Flow
-$95.7M
Cap. Flow %
-17.03%
Top 10 Hldgs %
67.51%
Holding
88
New
30
Increased
9
Reduced
14
Closed
29

Top Buys

Rank Stock Value
1
KDMN
Kadmon Holdings, Inc.
KDMN
+$12.1M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$6.11M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$5.66M
4
OBSV
ObsEva SA Ordinary Shares
OBSV
+$5.64M
5
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$5.08M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$22.1M
2
ASND icon
Ascendis Pharma A/S
ASND
+$15.3M
3
GYRE icon
Gyre Therapeutics
GYRE
+$7.59M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$7.42M
5
ARWR icon
Arrowhead Research
ARWR
+$6.84M

Sector Composition

Rank Sector Weight
1 Healthcare 67.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VIVE
51
DELISTED
VIVEVE MED INC
VIVE
$728K 0.13%
268
-417
-61% -$1.2M
CHRS icon
52
CALL
Coherus Oncology
CHRS
$222M
$700K 0.12%
+50,000
New +$716K
PTE
53
PUT
DELISTED
PolarityTE, Inc. Common Stock
PTE
$589K 0.1%
+1,000
New +$594K
ZYNE
54
PUT
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$487K 0.09%
+50,000
New +$513K
MNKD icon
55
PUT
MannKind Corp
MNKD
$1.17B
$204K 0.04%
107,500
-25,000
-19% -$46.8K
RMTI icon
56
PUT
Rockwell Medical
RMTI
$28.5M
$123K 0.02%
227
-2,546
-92% -$1.53M
ASXC
57
PUT
DELISTED
Asensus Surgical, Inc.
ASXC
$109K 0.02%
1,923
-11,923
-86% -$434K
OTLK icon
58
Outlook Therapeutics
OTLK
$171M
$25K ﹤0.01%
182
– –
ANIP icon
59
PUT
ANI Pharmaceuticals
ANIP
$1.82B
– –
-14,300
Closed -$833K
AXDX
60
CALL
DELISTED
Accelerate Diagnostics
AXDX
– –
-5,000
Closed -$1.14M
CRSP icon
61
PUT
CRISPR Therapeutics
CRSP
$4.88B
– –
-10,000
Closed -$457K
EDIT icon
62
PUT
Editas Medicine
EDIT
$407M
– –
-55,000
Closed -$1.82M
FXI icon
63
PUT
iShares China Large-Cap ETF
FXI
$4.35B
– –
-75,000
Closed -$3.54M
GKOS icon
64
PUT
Glaukos
GKOS
$10.1B
– –
-20,000
Closed -$617K
IWM icon
65
PUT
iShares Russell 2000 ETF
IWM
$81.5B
– –
-200,000
Closed -$30.4M
LLY icon
66
PUT
Eli Lilly
LLY
$1,000B
– –
-75,000
Closed -$5.8M
NTLA icon
67
PUT
Intellia Therapeutics
NTLA
$1.5B
– –
-75,000
Closed -$1.58M
QQQ icon
68
PUT
Invesco QQQ Trust
QQQ
$469B
– –
-85,000
Closed -$13.6M
RCKT icon
69
Rocket Pharmaceuticals
RCKT
$372M
– –
-350,000
Closed -$6.56M
SGMO
70
PUT
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-50,000
Closed -$950K
TEVA icon
71
PUT
Teva Pharmaceuticals
TEVA
$40.2B
– –
-25,000
Closed -$427K
TNDM icon
72
Tandem Diabetes Care
TNDM
$1.38B
– –
-1,346,360
Closed -$6.68M
UTHR icon
73
PUT
United Therapeutics
UTHR
$25.7B
– –
-25,000
Closed -$2.81M
QTTB icon
74
Q32 Bio
QTTB
$450M
– –
-4,389
Closed -$1.48M
MRTX
75
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-100,000
Closed -$3.07M
1 2
3
4

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q2 2018 Portfolio in Review

As of Q2 2018, Acuta Capital Partners held 88 positions worth $562M, down 8.3% from $612M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Acuta Capital Partners withdrew a net $95.7M in Q2 2018, closing 29 positions and reducing 14 holdings. Its most notable exit was AveXis, Inc. Common Stock, an estimated $7.42M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, up from 61% a quarter earlier.

Against the trend, Acuta Capital Partners opened a new position in Madrigal Pharmaceuticals worth $9.73M.

  • Acuta Capital Partners's largest Q2 2018 buy was Madrigal Pharmaceuticals: 34,803 shares worth $9.73M.
  • Acuta Capital Partners added most to Kadmon Holdings, Inc. in Q2 2018, an estimated $12.1M increase.
  • Acuta Capital Partners's biggest Q2 2018 reduction was Immunomedics Inc, cutting an estimated $22.1M.
  • Acuta Capital Partners fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $7.42M.
  • Acuta Capital Partners's ten largest holdings make up 68% of its $562M portfolio in Q2 2018.
  • Acuta Capital Partners opened 30 new positions and closed 29 in Q2 2018.
  • Acuta Capital Partners's portfolio value fell 8.3% quarter-over-quarter to $562M.

Based on Acuta Capital Partners's 13F filing for Q2 2018, filed 15 Aug 2018.